1. Scrip
  2. >>Therapy Areas

Incyte Enters A Data-Rich Year On Path To Portfolio Diversification

Myelofibrosis, Dermatology, Oncology Readouts Ahead

 
• By Mandy Jackson

Incyte’s Jakafi-dominated portfolio gained Opzelura as a second source of significant revenue in 2021. While further diversification has been limited, new and existing R&D assets may deliver upside in 2024.

Science Research as a Concept for Presentation
Incyte anticipates many trial readouts and other R&D milestones in 2024 • Source: Shutterstock

Incyte Corporation’s oral JAK1/2 inhibitor Jakafi (ruxolitinib) has grown to dominate the myelofibrosis market since its approval in 2011. For many years, it was the company’s only commercial asset, and it remains Incyte’s top seller by a wide margin, but it is facing loss of exclusivity (LOE) in 2028. However, while it is under pressure to diversify its revenue base through new products, the company expects to achieve milestones for multiple assets in 2024 that could reach the market ahead of the Jakafi LOE.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

 
• By Alaric DeArment

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.